Full-Time

Therapeutic Specialist

Miami

Crinetics Pharmaceuticals

Crinetics Pharmaceuticals

501-1,000 employees

Clinical-stage pharma developing rare endocrine therapies

Compensation Overview

$180k - $200k/yr

+ Discretionary annual target bonus + Stock options + ESPP + 401k match

Miami, FL, USA

In Person

Resident within Miami metro or South Florida preferred; willing to travel up to 50% of time.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Veeva
Word/Pages/Docs
Salesforce
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Crinetics Pharmaceuticals

See people who can refer or advise you

Requirements
  • Bachelor’s degree with at least 8 years of Pharmaceutical, Medical Device or Healthcare Industry sales experience
  • Ability to work independently and manage key account relationships
  • Demonstrated growth in sales while managing your own territory
  • Documented track record of consistently meeting or exceeding sales goals
  • Business acumen and strong comprehension of difficult clinical information
  • Ability to articulate complex clinical messages to Healthcare Providers in real time situations
  • Excellent organization and time management skills
  • Outstanding oral and written communication skills
  • Strong interpersonal and virtual engagement skills
  • Ability to work with a CRM tool (i.e., Veeva, Salesforce)
  • Independent, with an ability to work within a team
  • Strong Leadership Skills
  • Attention to detail and follow-through
  • Proficient in Microsoft Office (Word, Excel, PPT, etc.)
  • Travel up to 50% of your time
Responsibilities
  • Develop and execute a strategic business plan for a wide geographical area to effectively target, penetrate, and establish a network of relationships with key decision makers and stakeholders
  • Effectively call on physicians, nurses, nurse practitioners, physician assistants, pharmacists, etc., across multiple medical subspecialties
  • Call points include Endocrinologist, Primary Care Offices, IDNs, Academic Medical Centers, Pharmacies within health systems and hospitals, etc.
  • Fully understand and be able to communicate clear messages in complex clinical situations
  • Manage hybrid relationships through a mix of in-person (70+%) and virtual engagement – being able to leverage next gen ways of working to maximize efficiency
  • Utilize data sources to maximize strategies and efficiencies to capitalize on opportunities with the greatest ROI
  • Attain or exceed assigned sales and profit goal
  • Manage and track territory specific information through a CRM system
  • Other duties as assigned.
Desired Qualifications
  • Endocrinology Experience is preferred
  • Hospital Sales Experience
  • Knowledge of local/regional health systems
Crinetics Pharmaceuticals

Crinetics Pharmaceuticals

View

Crinetics Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare endocrine diseases and endocrine-related tumors. Its work centers on creating novel orally administered treatments, with CRN00808 for acromegaly currently in Phase 2 trials. The product approach involves identifying targets in endocrine pathways (often GPCRs), and engineering oral drug candidates that modulate these targets to treat conditions with few existing options. The company differentiates itself by concentrating on rare endocrine disorders and advancing candidates through clinical development, aiming to secure regulatory approvals and then pursue commercialization, often via partnerships or licensing with larger pharma players. Its goal is to provide effective, targeted therapies for patients with unmet endocrine needs and to bring approved medicines to market through disciplined clinical development and external collaborations.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

2008

Get referred to Crinetics Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex called Crinetics a $5 billion peak-sales asset, validating commercial potential.
  • Second-quarter 2026 revenue hit $25.12 million, far above estimates and up sharply year over year.
  • Crinetics presented six ENDO 2026 updates, strengthening conviction around PALSONIFY and atumelnant.

What critics are saying

  • Vertex agreed on July 6, 2026 to acquire Crinetics for $85 cash per share.
  • PALSONIFY uptake stays slow; endocrinologists still default to injectable somatostatin analogs.
  • Atumelnant faces Phase 3 failure risk, which would gut the deal thesis.

What makes Crinetics Pharmaceuticals unique

  • PALSONIFY is the first once-daily oral acromegaly therapy, approved September 2025.
  • Crinetics built a GPCR-focused endocrine platform spanning somatostatin and vasopressin pathways.
  • Atumelnant extends the franchise into congenital adrenal hyperplasia and ACTH-driven disorders.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Holidays

Unlimited Paid Time Off

PTO/vacation

Holiday/Vacation not?

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

3%

2 year growth

2%
MarketBeat
Aug 4th, 2026
Crinetics Pharmaceuticals (NASDAQ:CRNX) hits new 52-week high after better-than-expected earnings.

Crinetics Pharmaceuticals (NASDAQ:CRNX) hits new 52-week high after better-than-expected earnings. August 4, 2026 Key points. * Crinetics Pharmaceuticals shares reached a new 52-week high of $84 after the company reported quarterly EPS of -$1.14, beating estimates of -$1.18, while revenue of $25.12 million surpassed the $14.84 million consensus and rose 2,336.9% year over year. * Analyst sentiment is mixed, with a consensus "Hold" rating from five Buy, 11 Hold and one Sell ratings; the average price target is $81, while UBS raised its target to $85. * Institutional investors own 98.51% of the stock, with major holders including Wellington Management and Farallon Capital increasing their positions; two directors recently sold shares under pre-arranged trading plans. * MarketBeat previews the top five stocks to own by September 1st. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Tuesday after the company announced better than expected quarterly earnings. The stock traded as high as $84.00 and last traded at $83.95, with a volume of 799004 shares changing hands. The stock had previously closed at $83.76. The company reported ($1.14) EPS for the quarter, topping analysts' consensus estimates of ($1.18) by $0.04. Crinetics Pharmaceuticals had a negative net margin of 2,747.18% and a negative return on equity of 43.96%. The firm had revenue of $25.12 million during the quarter, compared to analyst estimates of $14.84 million. During the same period in the previous year, the business posted ($1.23) earnings per share. The business's revenue for the quarter was up 2336.9% on a year-over-year basis. Analysts set new price targets. A number of equities research analysts have weighed in on the stock. Lifesci Capital lowered shares of Crinetics Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 7th. UBS Group reiterated a "neutral" rating and set a $85.00 price objective (up from $55.00) on shares of Crinetics Pharmaceuticals in a research report on Tuesday, July 28th. Citizens Jmp cut Crinetics Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 7th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Crinetics Pharmaceuticals in a research report on Friday, July 17th. Finally, Piper Sandler cut shares of Crinetics Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 7th. Five research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Crinetics Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $81.00. Insider buying and selling. In other Crinetics Pharmaceuticals news, Director Stephanie Okey sold 6,900 shares of the firm's stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $35.67, for a total transaction of $246,123.00. Following the sale, the director owned 6,400 shares in the company, valued at approximately $228,288. This trade represents a 51.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Coelho Rogerio Vivaldi sold 3,000 shares of Crinetics Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $40.00, for a total transaction of $120,000.00. Following the transaction, the director directly owned 19,225 shares in the company, valued at $769,000. This represents a 13.50% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.80% of the company's stock. Institutional trading of Crinetics Pharmaceuticals. Institutional investors and hedge funds have recently modified their holdings of the company. Wellington Management Group LLP boosted its holdings in Crinetics Pharmaceuticals by 44.3% in the 3rd quarter. Wellington Management Group LLP now owns 8,381,991 shares of the company's stock worth $349,110,000 after buying an additional 2,574,683 shares during the period. Farallon Capital Management LLC raised its holdings in Crinetics Pharmaceuticals by 20.2% during the fourth quarter. Farallon Capital Management LLC now owns 6,933,098 shares of the company's stock valued at $322,736,000 after acquiring an additional 1,163,000 shares during the period. Janus Henderson Group PLC lifted its position in shares of Crinetics Pharmaceuticals by 1.8% in the first quarter. Janus Henderson Group PLC now owns 4,520,251 shares of the company's stock valued at $164,227,000 after acquiring an additional 79,560 shares in the last quarter. Paradigm Biocapital Advisors LP lifted its position in shares of Crinetics Pharmaceuticals by 8.8% in the third quarter. Paradigm Biocapital Advisors LP now owns 2,550,774 shares of the company's stock valued at $106,240,000 after acquiring an additional 207,221 shares in the last quarter. Finally, Siren L.L.C. boosted its stake in shares of Crinetics Pharmaceuticals by 26.3% in the first quarter. Siren L.L.C. now owns 1,903,636 shares of the company's stock worth $69,140,000 after acquiring an additional 396,000 shares during the period. 98.51% of the stock is currently owned by institutional investors. Crinetics Pharmaceuticals price performance. The firm has a 50-day moving average of $55.09 and a 200-day moving average of $46.39. The stock has a market cap of $8.85 billion, a PE ratio of -16.37 and a beta of 0.12. About Crinetics Pharmaceuticals. Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company's proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics' research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence. The company's lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Crinetics Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crinetics Pharmaceuticals wasn't on the list. While Crinetics Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Informa TechTarget
Jul 22nd, 2026
Vertex was sole bidder in high-premium Crinetics acquisition.

Vertex was sole bidder in high-premium Crinetics acquisition. Analysts expect new details on the lead-up to the deal "are likely to reignite" investor scrutiny that Vertex overpaid in what's poised to be its largest-ever transaction. Published July 22, 2026 Vertex Pharmaceuticals was the lone bidder in a planned, $10 billion acquisition that has some investors questioning whether the biotechnology giant overpaid on its largest-ever deal. Financial documents filed Tuesday provide an inside look at the tie-up between Vertex and Crinetics Pharmaceuticals, a California-based company specializing in endocrine drugs. Crinetics has one marketed therapy for an uncommon hormonal condition, as well as an experimental medicine in late-stage testing for a rare genetic disease called congenital adrenal hyperplasia. Vertex estimates that, together, the two drugs could generate north of $5 billion a year at their peak. Yet, at a 102% premium, the $85-per-share offer is one of the biggest markups this year for a biotech buyout, according to BioPharma Dive data. When Vertex shares dipped after the deal's announcement, analysts suspected that investors weren't happy with the price tag. The deal value "assumes a bullish case outcome" for Crinetics' drugs, and will likely stir debates about whether Vertex "paid full price or even a rich price," Stifel analyst Paul Matteis wrote in a July 6 note to clients. The newly released documents "are likely to reignite" that investor scrutiny, according to RBC Capital Markets analyst Brian Abrahams. The seeds for the acquisition, like many biopharma deals, were planted at the industry's annual bellwether event: the J.P. Morgan Healthcare Conference. Crinetics' filings describe how, during that mid-January conference, its own representatives met with Vertex's external innovation team "as part of ordinary course business development activity." A couple months passed before Vertex, on March 14, reached out to Crinetics' CEO R. Scott Struthers about a potential transaction. By March 24, Vertex submitted a proposal to buy all of the biotech's outstanding shares for $78 apiece, reflecting a 125% premium to the stock's most recent closing price. Crinetics quickly tapped Leerink Partners and J.P. Morgan to serve as financial advisors, and, together, this team spent the next 10 days evaluating the proposal. Crinetics' board of directors acknowledged the sizable premium, but believed that, since this was an initial offer, Vertex would be willing to go higher. On April 5, the board rejected the bid but cleared Struthers to tell Vertex they may reconsider if terms were "significantly improved." On April 19, Vertex revised its offer to $83 per share, which, by that time, represented a 102% premium. But it still didn't pass muster. Crinetics' board members knocked down the new proposal three days later. And, with adviser help, they came up with a list of six other companies that might be interested in - and have the resources to finance - a substantial transaction. In the final week of April, three of those six counterparties conveyed they didn't want to make a deal. Another, "Party A," did express interest. By May 1, however, it determined it couldn't propose a transaction worth north of $6 billion. After some back and forth, "Party A" dropped out of the deal process. The final two contenders followed suit the next week. From May 8-28, Crinetics and Vertex continued to exchange due diligence information. On that latter date, Vertex upped its offer to $84.50 per share, or a 130% premium. The Crinetics board concluded that, because this new offer would be dilutive to Vertex's earnings per share in the near term, it was likely at or near the maximum Vertex would be willing to pay. Still, the board wanted to see if it could squeeze out a little more, so they relayed a counterproposal of $87 per share. Vertex representatives said further due diligence was required before they could put forward a final offer. On June 19, a senior representative contacted Struthers and said Vertex was prepared to buy Crinetics for $85 per share. Crinetics tried to eke out one more dollar per share, but Vertex responded that the $85 price point was its best and final offer. Crinetics' board found this acceptable, and after squaring away other final concerns, the companies reached an agreement on July 6.

GlobeNewswire
Jul 21st, 2026
Shareholder alert: Ademi LLP investigates whether Crinetics pharmaceuticals, inc. is obtaining a fair price for public shareholders.

Shareholder alert: Ademi LLP investigates whether Crinetics pharmaceuticals, inc. is obtaining a fair price for public shareholders. July 21, 2026 07:37 ET | Source: Ademi LLP MILWAUKEE, July 21, 2026 (GLOBE NEWSWIRE) - Ademi LLP is investigating Crinetics (Nasdaq: CRNX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Vertex. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. Crinetics shareholders will receive $85.00 per share in cash, representing a total equity value of approximately $10.0 billion, or $8.8 billion net of estimated cash acquired. Crinetics insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Crinetics by imposing a significant penalty if Crinetics accepts a competing bid. We are investigating the conduct of the Crinetics board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes. Ademi LLP Guri Ademi Toll Free: (866) 264-3995 Fax: (414) 482-8001

Business Wire
Jul 7th, 2026
Vertex to Acquire Crinetics Pharmaceuticals

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discove...

BioWorld
Jul 7th, 2026
Vera's Trutakna wins FDA nod as first dual inhibitor for IgAN.

Vera's Trutakna wins FDA nod as first dual inhibitor for IgAN. July 7, 2026 Vera Therapeutics Inc. looks to get an almost five-month head start over a competitor, Vertex Pharmaceuticals Inc., as the U.S. FDA cleared its Trutakna (atacicept) as the first dual BAFF/APRIL inhibitor for treating immunoglobulin A nephropathy (IgAN). The accelerated approval, which came on the July 7 PDUFA date, indicates Trutakna for use in reducing proteinuria in adults with primary IgAN at risk for disease progression. The drug is administered once weekly via auto-injector. A confirmatory trial, dubbed Origin 3, already is underway, with results expected in the third quarter of this year, putting a potential full approval in 2027. The accelerated nod was based on reduction in proteinuria, so regulators will be looking to see whether Trutakna slows kidney function decline over the long term, as assessed by estimated glomerular filtration rate. Endocrinology becomes Vertex's fifth pillar with $10B Crinetics buy. Representing the fourth largest biopharma M&A announced in 2026, Vertex Pharmaceuticals Inc. offered $85 per share in cash, or about $10 billion, to buy endocrine specialist Crinetics Pharmaceuticals Inc., adding the acromegaly drug Palsonify and a phase III asset, atumelnant, for congenital adrenocorticotropic hyperplasia. Together, the two products could bring upwards of $5 billion in peak sales to Vertex, which is adding endocrinology as its fifth commercial pillar, along with cystic fibrosis, hematology, pain and renal. Crinetics' shares (NASDAQ:CRNX) climbed 99%, or $41.49, to $83.52 by midday July 6, while Vertex's shares (NASDAQ:VRTX) traded downward by $3.36 to $526.55. Both boards unanimously approved the transaction, expected to close in the third quarter. Tvardi skyrockets on phase I data; broader swath for STAT3? Shares of Tvardi Therapeutics Inc. (NASDAQ:TVRD) were trading up 46%, or 93 cents, to sell at $2.94 on phase I results for TTI-109, the company's next-generation STAT3 inhibitor, a phosphate prodrug of TTI-101 designed to improve delivery and tolerability while preserving the parent compound's mechanism of action. TTI-101 failed in phase II against idiopathic pulmonary fibrosis last October, when problematic gastrointestinal (GI) effects surfaced. With TTI-109, the latest study confirmed fast conversion, dose-proportional pharmacokinetics (exposures above the STAT3 inhibitory concentration 50 [IC50]), and - in an exploratory pharmacodynamic analysis - reductions of up to 60% in STAT3-driven immune cell populations across Th17, Tfh and B-cell subsets. Tvardi's early stage win supports advancement into phase II exploration, the company said. Taking aim at the STAT3 target, which is well-validated in cancer, could mean the drug will work in GI as well as dermatologic indications. EG427 raises $37.7M series C for HSV gene therapy in chronic bladder conditions. The gene therapy specialist formerly known as EG427 has a new name and fresh momentum, after closing a €33 million (US$37.7 million) series C that will further advance clinical development of the lead program in chronic neuro-urology indications. Now named Cyllene Therapeutics, the funding was raised on the back of data from the company's phase Ib/ IIa trial of EG-110A, in which the 88% reduction in urinary incontinence episodes in patients with neurogenic bladder seen at week 12, was maintained at 24 weeks follow-up. Those data were published in February 2026 and since then there has been sustained efficacy for more than one year in the first 10 patients enrolled in the ongoing study, which is treating neurogenic detrusor overactivity caused by spinal cord injury. Opus aligns with FDA on rare eye disease gene therapy trial. Opus Genetics Inc. has secured U.S. FDA alignment on an eight-patient phase III trial of its lead gene therapy, OPGx-LCA5, for an ultra-rare form of inherited childhood blindness. The FDA feedback further supported a potential BLA submission for the gene augmentation therapy based on efficacy data from the six-month primary endpoint, with 12-month durability data to be submitted during the review process. Opus CEO George Magrath said the feedback, rendered at the end of the company's type B Rare Disease Evidence Principles meeting with the FDA, provided a "clear roadmap" for regulatory filing and potential approval. 340B reforms on the congressional table. After years of hearings, finger-pointing and litigation, the U.S. Congress finally seems to be getting serious about fixing the 340B prescription drug discount program, which today is the second largest federal drug program. In introducing a bipartisan proposal yesterday to modernize the program that was created in 1992 to help safety-net hospitals and clinics provide services to low-income patients, Rep. Scott Peters, D-Calif., said, "The Secure 340B Act closes the loopholes that have allowed the program to drift from its mission, stops the legal chaos that plagues the program today, and puts in place the kind of transparency and accountability that will keep 340B strong for decades to come." The House proposal comes a week after Sen. Bill Cassidy, R-La., released a discussion draft of his own comprehensive reform proposal, the 340B for Patients Act. 'Target-high but uptake-defective' state identified in ADC resistance. Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma Inc./Pfizer Inc.), and possibly to ADCs more broadly. Urothelial cancer drug Padcev, which targets the cell adhesion molecule Nectin-4, was approved in 2019 and is currently one of Pfizer's top 10 medicines and vaccines, generating $1.94 billion in 2025. Investigators from Sun Yat-sen University Cancer Center have reported that some cells expressing high levels of target protein were nevertheless resistant to Padcev due to the activity of the enzyme AKR1C1, which reduced endocytosis of the Padcev-bound Nectin-4 and increased its packaging into extracellular vesicles and export from cells. Science fiction realized: BCI tech is here. After decades of clinical research and false starts, have Brain-Computer Interface (BCI) systems finally arrived? With developments accelerating in the field, BioWorld's special series explores the advancements in the space, looking at the implanted technologies, their potential to transfer care, what's driving investor interest and the challenges ahead. Also in the news. Abcellera, Acadia, Agenus, Anixa, Ascelia, Astex, Baiyunshan, Brii, Capsovision, Corbus, Forus, Genentech, Incyte, Invivyd, Median, Natera, Pharmaessentia, Pharvaris, Roche, Sanyou, Scribe, Star, Tempramed, Vega, Vicore, Visby To read more on related topics, click on one of the words below.